VEGFA and retinal vein occlusion: Over the past two decades, intravitreal injections of anti-vascular endothelial growth factor (anti-VEGF) agents have become increasingly common, particularly in the treatment of neovascular age-related macular degeneration, retinal vein occlusion, and diabetic macular edema.